ERBB2 and breast cancer: These current findings demonstrate that targeting ER signalling with the pure anti-ER fulvestrant can both suppress and induce gene and protein expression in ER-positive, ErbB2 low-expressing and ErbB2-overexpressing breast cancer cell lines.